Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 ISCOMATRIX vaccine in advanced melanoma
NCT00518206Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Nov 2003
- Primary completion
- Jan 2010
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of NY-ESO-1 ISCOMATRIX vaccine in melanoma, sponsored by Ludwig Cancer Research. Started Nov 2003; status: completed.
02
Drugs
NY-ESO-1 ISCOMATRIX vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00518206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00518206.